Crossmark

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study

Crossref DOI link: https://doi.org/10.1186/s40001-025-02406-9

Published Online: 2025-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wan, Bangbei

Zhou, Zhi

Ma, Ning

Lu, Weiying
Funding

Funding for this research was provided by:

Research and Cultivation Fund of Hainan Medical University (HYPY2020015)

Hainan Province Clinical Medical Center (QWYH202175)

Natural Science Foundation of Hainan Province (820RC771)

Key R&D Projects of Hainan Province (ZDYF2022SHFZ074)

Specific Research Fund of The Innovation Platform for Academicians of Hainan Province (YSPTZX202311)
License Information

Text and Data Mining valid from 2025-02-27

Version of Record valid from 2025-02-27
More Information

Article History

Received: 9 January 2024

Accepted: 24 February 2025

First Online: 27 February 2025

Declarations

:

: Ethical approval and consent were not required as this study was based on publicly available data.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below